A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.
ICOS
chemotherapy
cyclophosphamide
humanized mice
immunotherapy
regulatory T cells
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
03
01
2019
revised:
01
03
2019
accepted:
05
03
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
Mice reconstituted with a human immune system and bearing human tumors represent a promising model for developing novel cancer immunotherapies. Here, we used mass cytometry and multi-parametric flow cytometry to characterize human leukocytes infiltrating a human breast cancer tumor model in immunocompromised NOD.SCID.γc-null mice reconstituted with a human immune system and compared it to samples of breast cancer patients. We observed highly activated human CD4
Identifiants
pubmed: 31143518
doi: 10.1080/2162402X.2019.1596005
pii: 1596005
pmc: PMC6527285
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1596005Références
J Immunol. 2005 May 15;174(10):6477-89
pubmed: 15879151
J Immunol. 2008 Mar 1;180(5):2967-80
pubmed: 18292519
Immunity. 2008 Jun;28(6):870-80
pubmed: 18513999
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
J Immunol. 2009 Mar 15;182(6):3349-56
pubmed: 19265111
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196
Eur J Immunol. 2009 Aug;39(8):2136-45
pubmed: 19572320
Cancer Res. 2010 Dec 1;70(23):9581-90
pubmed: 21098714
Int J Cancer. 2011 Nov 1;129(9):2194-206
pubmed: 21544806
Semin Immunopathol. 2011 Jul;33(4):369-83
pubmed: 21611872
J Clin Invest. 2011 Sep;121(9):3609-22
pubmed: 21841316
PLoS One. 2011;6(9):e24420
pubmed: 21935406
Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
J Pathol. 2011 Dec;225(4):565-73
pubmed: 22025213
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Cancer Res. 2012 Oct 15;72(20):5240-9
pubmed: 22850422
Cancer Res. 2012 Dec 1;72(23):6130-41
pubmed: 23026134
Sci Transl Med. 2012 Nov 7;4(159):159ra149
pubmed: 23136044
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
J Clin Invest. 2013 Jun;123(6):2447-63
pubmed: 23728179
Oncoimmunology. 2013 Mar 1;2(3):e23185
pubmed: 23802069
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
Sci Transl Med. 2014 Jan 1;6(217):217ra3
pubmed: 24382895
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
J Exp Med. 2014 Apr 7;211(4):715-25
pubmed: 24687957
Immunol Cell Biol. 2014 Jul;92(6):475-80
pubmed: 24732076
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
Cancer Cell. 2014 Nov 10;26(5):638-52
pubmed: 25446897
Oncogene. 2016 Jan 21;35(3):290-300
pubmed: 25893296
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Cancer Res. 2015 Sep 1;75(17):3466-78
pubmed: 26113085
PLoS One. 2015 Sep 25;10(9):e0138420
pubmed: 26407077
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Oncoimmunology. 2015 Dec 10;5(3):e1090075
pubmed: 27141347
Cancer Res. 2016 Jul 1;76(13):3684-9
pubmed: 27197182
Cancer Res. 2016 Aug 15;76(16):4648-60
pubmed: 27246829
JAMA Oncol. 2016 Oct 1;2(10):1354-1360
pubmed: 27355489
Front Immunol. 2016 Aug 10;7:304
pubmed: 27559335
Cancer Res. 2016 Nov 1;76(21):6153-6158
pubmed: 27587540
Int J Cancer. 2017 Feb 1;140(3):686-695
pubmed: 27756099
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
Cancer Res. 2017 Mar 1;77(5):1108-1118
pubmed: 28122327
Immunity. 2017 Apr 18;46(4):577-586
pubmed: 28410988
Science. 2017 Jun 9;356(6342):
pubmed: 28473638
Cancer Res. 2017 Aug 15;77(16):4378-4388
pubmed: 28611044
Nat Med. 2018 Feb;24(2):144-153
pubmed: 29309059
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Diabetes. 1993 Nov;42(11):1574-8
pubmed: 8405697